Advertisement

Addressing Changes Associated with Technology Transfer: A Case Study

  • Michele M. Myers
  • Camille Keating
  • Joann Bannon
  • Donald S. Neblock
  • Peter W. Wojciechowski
Chapter
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume XI)

Abstract

REMICADE® is a chimeric monoclonal antibody directed against TNF-α. It was the first drug product in the class of TNF-α inhibitors approved for use in humans. It is a lyophilized formulation of the drug substance, infliximab, and is approved for the treatments of autoimmune disorders including rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, and psoriatic arthritis.

Production of REMICADE was first approved in 1998 at Centocor’s Leiden, The Netherlands, facility. Soon after approval of the Leiden manufacturing facility, plans to scale-up and add a second manufacturing site in Malvern, Pennsylvania, were initiated. Comparability of the products prepared at the two facilities was demonstrated. The FDA approved the Malvern facility in April 2002. It was approved by the EMEA in 2003.

Keywords

Technology Transfer Feed Stream Cation Exchange Chromatography Cation Exchange Column Spin Filter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments.

The authors gratefully acknowledge Larry Doolittle, Paul Gahr, and Karen Fixler for their contributions to the project and Timothy Laverty for useful discussions.

Copyright information

© American Association of Pharmaceutical Scientists 2010

Authors and Affiliations

  • Michele M. Myers
    • 1
  • Camille Keating
    • 2
  • Joann Bannon
    • 3
  • Donald S. Neblock
    • 3
  • Peter W. Wojciechowski
    • 4
  1. 1.Centocor Research & DevelopmentRadnorUSA
  2. 2.ImClone SystemsBranchburgUSA
  3. 3.Centocor Research & DevelopmentMalvernUSA
  4. 4.Advanced Technologies and Regenerative Medicine, LLCRaynhamUSA

Personalised recommendations